 Immunoconjugates
"Immunoconjugates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
| Descriptor ID |
D018796
|
| MeSH Number(s) |
D12.776.124.790.651.114.580 D12.776.377.715.548.114.580
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunoconjugates".
Below are MeSH descriptors whose meaning is more specific than "Immunoconjugates".
This graph shows the total number of publications written about "Immunoconjugates" by people in this website by year, and whether "Immunoconjugates" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 | | 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 3 | 0 | 3 | | 2003 | 1 | 1 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 2 | 2 | 4 | | 2006 | 3 | 0 | 3 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 3 | 0 | 3 | | 2010 | 1 | 1 | 2 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 0 | 1 | | 2013 | 3 | 1 | 4 | | 2014 | 2 | 1 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 4 | 0 | 4 | | 2017 | 9 | 1 | 10 | | 2018 | 6 | 1 | 7 | | 2019 | 3 | 1 | 4 | | 2020 | 4 | 0 | 4 | | 2021 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunoconjugates" by people in Profiles.
-
Hann CL, Burns TF, Dowlati A, Morgensztern D, Ward PJ, Koch MM, Chen C, Ludwig C, Patel M, Nimeiri H, Komarnitsky P, Camidge DR. A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC. J Thorac Oncol. 2021 09; 16(9):1582-1588.
-
Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2021 06 01; 106(6):1705-1713.
-
Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021 06; 32(6):746-756.
-
Daver N, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E175-E179.
-
Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020 12; 31(12):1709-1718.
-
Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Clin Cancer Res. 2020 11 15; 26(22):6028-6038.
-
Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, Camidge DR, Iwata H, Powell CA. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Aug; 183(1):23-39.
-
Amaya ML, Jimeno A, Kamdar M. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. Drugs Today (Barc). 2020 Apr; 56(4):287-294.
-
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 01 10; 38(2):155-165.
-
Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, Hawthorne T, Crowley E, Moscow JA, Reid JM, Villalobos V, Randall RL, Gorlick R, Janeway KA. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. Eur J Cancer. 2019 11; 121:177-183.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|